Kwang Tai Medicinal Co., Ltd. Q4 2025 EPS NT$8.22
Kwang Tai Medicinal Co., Ltd. reported Q4 2025 earnings per share (EPS) of NT$8.22, with revenue of NT$10.252 billion and net profit after tax of NT$1.861 billion.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Kwang Tai Medicinal Co., Ltd. (Stock Code: 1707), operating in the biotechnology and healthcare industry, announced its financial results for the fourth quarter of 2025. The company posted basic earnings per share of NT$8.22, with operating revenue reaching NT$10.252 billion and net profit after tax at NT$1.861 billion.
FAQ
What is Kwang Tai Medicinal's stock code?
Kwang Tai Medicinal's stock code is 1707.
What industry does Kwang Tai Medicinal operate in?
Kwang Tai Medicinal operates in the biotechnology and healthcare industry.
What was Kwang Tai Medicinal's revenue in Q4 2025?
Kwang Tai Medicinal's revenue in Q4 2025 was NT$10.252 billion.
What was Kwang Tai Medicinal's net profit after tax in Q4 2025?
Kwang Tai Medicinal's net profit after tax in Q4 2025 was NT$1.861 billion.